Peak Bio, Inc.
Peak Bio, Inc. (PKBO): 2 pipeline candidates · ~3 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
2.5 months
D/E -1.08 · 23% dilution
Lead: Preclinical
2 candidates
N/A
N/A
A transparent, data-derived signal for Peak Bio, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$922K
Quarterly Burn
$1.4M
Runway
2.5 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Frequently asked questions
How many drug candidates are in Peak Bio, Inc.'s pipeline?
Peak Bio, Inc. (PKBO) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Peak Bio, Inc.'s lead drug candidate?
Peak Bio, Inc.'s most advanced tracked candidate is php-303 (Preclinical) for Acute respiratory distress syndrome (ARDS).
What is Peak Bio, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Peak Bio, Inc. has approximately 2.5 months of cash runway.
Get the full picture on Peak Bio, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.